Aurélien Lambert retweeted
Does adding chemoradiation to neoadjuvant #mFOLFIRINOX benefit patients with #BRPC?
No, according to results from the phase 2 #PANDAS/PRODIGE 44 trial presented by @aurelienlambert of @icl_lorraine.
Learn more here: buff.ly/3Y7Nbab
Aurélien Lambert retweeted
#ESMO2024 : Focus sur les cancers digestifs
Les essais PODIUM, TOPGEAR et PANDAS, avec @aurelienlambert
ms.spr.ly/6185m5OJH
Aurélien Lambert retweeted
The addition of neoadjuvant CRT did not improve outcomes in patients receiving mFOLFIRINOX and surgery for borderline resectable #pancreaticcancer. These results were presented at #ESMO2024 by @aurelienlambert from @icl_lorraine. #ESMO24 #pancsm #gicsm cancertherapyadvisor.com/rep…
Aurélien Lambert retweeted
Dear Colleagues,
The @OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 GI Abstracts to be Presented at #ESMO24
This List Curated by: #OncoAlertAF Leads
@realbowtiedoc 🇺🇸
@Erman_Akkus 🇹🇷
@weoncologists 🇺🇸
1141O - Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
Presenter: Jennifer Chan of @DanaFarber (Boston, United States of America🇺🇸)
Discussant Nicola Fazio of @IEOufficiale (Milan, Italy🇮🇹)
Date: Mon, 16.09.2024
Lecture Time 14:45 - 14:55
LBA2 – POD1UM-303/INterAACT 2: Phase 3 Study of Retifanlimab with Carboplatin Paclitaxel (C-P) in patients (Ptts) with Inoperable Locally Recurrent or Metastatic Carcinoma of the Anal Canal (SCAC) Not Previously Treated with Systemic Chemotherapy (Chemo)
Presenter: Sheela Rao from @royalmarsdenNHS (London, United Kingdom🇬🇧)
Discusssant @ModestDominik (Berlin, Germany🇩🇪)
Date: Sat, 14.09.2024
Lecture Time 16:52 - 17:04
504O - IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort
Presenter: @CdlFouchardiere (Marseille, Cedex 09, France🇫🇷)
Discussant @JenSeligmann (Leeds, United Kingdom, Yorkshire🇬🇧)
Date: Sun, 15.09.2024
Lecture Time 09:30 - 09:40
LBA24 - Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2.
Presenter: @MyriamChalabi (Amsterdam, Netherlands🇳🇱 )
Discussant @JenSeligmann (Leeds, United Kingdom, Yorkshire🇬🇧)
Date: Sun, 15.09.2024
Lecture Time 09:10 - 09:20
LBA58 - A randomized phase III trial of perioperative chemotherapy (periop CT) with or without
preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results
Presenter: Trevor Leong (Melbourne, Australia🇦🇺)
Discussant @tfleitask (Valencia, Spain🇪🇸)
Date: Sat, 14.09.2024
Lecture Time 08:30 - 08:40
LBA60 - Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA)
Presenter: Zhi Peng (Beijing, China🇨🇳)
Discussant @RadkaObermanno1 (Brno,Czech Republic🇨🇿)
Date: Mon, 16.09.2024
Lecture Time 08:30 - 08:35
LBA62 - Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II PANDAS/PRODIGE 44
Presenter: @aurelienlambert (Vandoeuvre-lès-Nancy, France🇫🇷)
Discussant @rachnatshroff (Tucson, United States of America🇺🇸)
Date: Fri, 13.09.2024
Lecture Time 16:45 - 16:55
LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study
Presenter: Josep Llovet (Barcelona, Spain🇪🇸) Discussant @DrAngelaLamarca (Madrid, Spain🇪🇸)
Date: Sat, 14.09.2024
Lecture Time 17:36 - 17:48
LBA59 - Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial Presenter: Sylvie Lorenzen of @TU_Muenchen (Munich, Germany🇩🇪)
Discussant @tfleitask (Valencia, Spain🇪🇸)
Date Sat, 14.09.2024
Time 8:40 - 8:50
LBA25 - Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
Presenter: Stefan Kasper-Virchow of @UniklinikEssen (Essen, Germany🇩🇪)
Discusant @ClaraMontagut (Barcelona, Spain🇪🇸)
Date: Sun, 15.09.2024
Time 14:45 - 14:55
@OncoAlert GI Faculty 🚨
@Aiims1742 @pashtoonkasi @CathyEngMD @marklewismd @manjuggm @stacy_hurt @ARosen380 @KoheiShitara @GillSharlene @BenWestphalen
#OncoAlertAF
@nataliagandur @acampsmalea @BiagioRicciutMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @lungoncdoc @bavilima @realbowtiedoc @Erman_Akkus @DrFMartinelli @Lucarecco @orellanauro
Aurélien Lambert retweeted
Qui de mieux que les utilisateurs pour parler de PandaLab Pro ?
Nous sommes fiers de partager avec vous la satisfaction de nos clients vis-à-vis de notre solution de coordination pour les professionnels de santé.
Merci pour votre confiance. 🐼
#esanté #coordination #health
Aurélien Lambert retweeted
Botensilimab plus balstilimab in relapsed/ refractory MSS mCRC
@Nature
doi.org/10.1038/s41591-024-0…
🔎phs 1 trial, 148 heavily pre-treated pts
👉ORR 17%, DCR 61%
👉mPFS 3.5, mOS 20.9 mo
👉TRAEs 89%
👉No response in pts w/ liver mets
🔎New MOA -> promising
Aurélien Lambert retweeted
Ecstatic and proud to share the NICHE-2 results, now published in @NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. @HaanenJohn
nej.md/3Ku4X0H
Aurélien Lambert retweeted
📚🎉 Votre faculté est sur Youtbe ! 📚🎉 📢 Rejoignez notre chaîne YouTube FacdeMedecine_Nancy : découvrez nos moments forts, des vidéos explicatives pour vos cours, les témoignages étudiants et bien plus ! Abonnez-vous dès maintenant ! 📽️🔔 Lien : youtube.com/@FacdeMedecine_N…
Aurélien Lambert retweeted
Puisque menacée de mort par des idiots dont l'intelligence est absente de leur cerveau plein d'eau, il est donc crucial de partager unanimement la caricature de @cocoboer et de lui apporter un soutien sans réserve. Ce réseau doit être innondé car c'est encore une fois la liberté et la vie d'une femme qui sont salies.
nouvelobs.com/societe/202403…
Aurélien Lambert retweeted
⚫️ C’est avec une vive émotion que nous vous faisons part du décès du Professeur Pierre-Edouard Bollaert, survenu mardi 30 janvier 2024 à l’âge de 68 ans.
La communauté médicale et hospitalière se souvient d’un collègue compétent, qui a énormément apporté aux équipes médicales.
Aurélien Lambert retweeted
This month’s Lancet Gastro cover highlights our review 🔥
Let’s better understand this disease to improve our care.
#PancreaticCancer
Our December issue is now available at www.the lancet.com/gastrohep! Content includes #DEI, treatments for #NALFD #MASLD, #LynchSyndrome, #haemochromatosis, #immunotherapy for #PancreaticCancer, & more…
#GITwitter #LiverTwitter #MedTwitter
Aurélien Lambert retweeted
The new french guidelines for oesophageal cancer are published in Digestive and Liver Disease
sciencedirect.com/science/ar…
Aurélien Lambert retweeted
[#Expertise]
L'@icl_lorraine au congrès international de l'#ASCO2023
𝗖𝗮𝗻𝗰𝗲𝗿𝘀 𝗱𝘂 𝗿𝗲𝗰𝘁𝘂𝗺 𝗲𝘁 𝗱𝘂 𝗽𝗮𝗻𝗰𝗿𝗲́𝗮𝘀 : 𝗱𝗲𝘀 𝗮𝘃𝗮𝗻𝗰𝗲́𝗲𝘀 𝗽𝗿𝗼𝗺𝗲𝘁𝘁𝗲𝘂𝘀𝗲𝘀 par le Pr T. Conroy et le Dr A. Lambert
En savoir plus : vu.fr/oUcl
@GroupeUnicancer
Aurélien Lambert retweeted
The 7 year Follow up study PRODIGE 23 confirms the OS improvement for patients with LA rectal cancer. Congratulations to Pr Thierry Conroy and to the PRODIGE partnership @GroupeUnicancer #gercor @ffcd_cancerdig @ASCO 2023
Aurélien Lambert retweeted
🔴 Covid-19 : C'est aujourd'hui avéré, la première étude sur l’hydroxychloroquine a bien été falsifiée par l'IHU de Marseille.
Et c'est loin d'être la seule escroquerie.
Le désastre Didier Raoult : explications dans l'édito de #PatrickCohen dans #CàVous ⬇️
Aurélien Lambert retweeted
Let's be clear. Eli Lilly should apologize for increasing the price of insulin by over 1,200% since 1996 to $275 while it costs less than $10 to manufacture. The inventors of insulin sold their patents in 1923 for $1 to save lives, not to make Eli Lilly's CEO obscenely rich.
This quoted post is unavailable.








































